​
Novacyt
S.A.
("Novacyt", the "Company" or
the "Group")
Liquidity Agreement Monthly
Update and Total Voting Rights
Paris, France, Eastleigh and Manchester, UK - 1 October 2024
- Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international specialist in clinical
diagnostics, announces its monthly update in relation to ordinary
shares traded under its ongoing liquidity agreement with Invest
Securities SA (the "Liquidity Agreement"). The Liquidity Agreement
is governed by French law and is further summarised
below.
During the period from 1 September
to 30 September 2024, Invest Securities purchased 82,719 ordinary
shares at a maximum price of €1.11 and a minimum price of €0.70 and
sold 27,145 ordinary shares at a maximum price of €1.16 and a
minimum price of €0.70 under the Liquidity Agreement. The total
number of ordinary shares in the Company, which are held in
treasury as at close of business on 30 September 2024, is
76,010.
Total Voting Rights
The total number of ordinary shares
in the Company is 70,626,248. This figure may be used by
shareholders as the denominator for calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the Company pursuant to Article L.
223-7 of the French Commercial Code and the Company's Articles. The
Company is not subject to the disclosure guidance and transparency
rules made by the Financial Conduct Authority under Part VI of
FSMA.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn Rees, Chief Executive
Officer
|
Via Walbrook
PR
|
|
Steve Gibson, Chief Financial
Officer
|
|
|
SP
Angel Corporate Finance LLP (Nominated Adviser and
Broker)
|
+44 (0)20
3470 0470
|
|
Matthew Johnson / Charlie Bouverat
(Corporate Finance)
Vadim Alexandre / Rob Rees
(Corporate Broking)
|
|
|
|
|
|
Deutsche Numis (Joint
Broker)
|
+44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick
Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/
y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR
(Financial PR & IR)
Stephanie Cuthbert / Paul McManus
/
Phillip Marriage / Alice
Woodings
|
+44 (0)20
7933 8780 or novacyt@walbrookpr.com
+44
(0)7796 794 663 / +44 (0)7980 541 893
+44
(0)7867 984 082 / +44 (0)7407 804 654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an
international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily
focused on the delivery of genomic medicine. The Company
develops, manufactures, and commercialises
a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions
from sample to result across multiple sectors including human
health, animal health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical in vitro diagnostic products,
workflows and services focused on three therapeutic
areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex
winter respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size selection DNA
sample preparation platforms and rapid PCR
machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
MyGo: real-time quantitative PCR
(qPCR) instruments
|
|
Research Use Only
|
Range of services for the research industry:
· Design,
manufacture, and supply of high-performance qPCR assays and
workflows for use in human health, agriculture, veterinary and
environmental, to support global health organisations and the
research industry
·
Pharmaceutical research services: whole genome sequencing (WGS) /
whole exome sequencing (WES)
|
Novacyt is headquartered in Vélizy
in France with offices in the UK (in Stokesley, Eastleigh and
Manchester), Singapore, the US and Canada and has a commercial
presence in over 65 countries. The Company is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock
Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com
Further information on the Liquidity
Agreement
On 12 September 2016, the Company
and Invest Securities entered into the Liquidity Agreement pursuant
to which Invest Securities provides liquidity services in relation
to the ordinary shares to the Company. Invest Securities may
purchase ordinary shares on behalf of the Company under the
agreement, subject to approval from Shareholders as to the price at
which ordinary shares can be brought back and the aggregate amount
that the Company may provide to Invest Securities to purchase such
ordinary shares.
Shareholder approval was granted at
the Shareholders' meeting held on 18 July 2024 for the purchase of
ordinary shares by Invest Securities under the agreement at a
maximum purchase price per ordinary shares of €5.00 for an
aggregate maximum purchase price of €200,000 and for 18 months from
the date of the approval. Under the agreement, Invest Securities
must act completely independently of the Company and the Company
must not communicate with the employees of Invest Securities who
are responsible for performing the agreement. Invest Securities is
paid €10,000 per annum for its services under the liquidity
agreement. The agreement has an initial term of two years, with a
rolling extension of one year thereafter. The agreement can be
terminated by either party at the end of each such period subject
to two months' prior notice. The Liquidity Agreement is governed by
French law. Ordinary shares purchased by Invest Securities are
either cancelled or held as treasury shares (which are non-voting
and do not rank for dividends).